Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure.
D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004077:Digoxin / Q000627:therapeutic use; D004341:Drug Evaluation; D005292:Ferricyanides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005665:Furosemide / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011652:Pulmonary Circulation / Q000187:drug effects; D012770:Shock, Cardiogenic / Q000150:complications / Q000188:drug therapy*; D013148:Spironolactone / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D005292:Ferricyanides; D014665:Vasodilator Agents; D013148:Spironolactone; D009569:Nitric Oxide; D004077:Digoxin; D005665:Furosemide; D007548:Isosorbide Dinitrate